These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Elect seven members of our Board of Directors to hold one-year terms;
|
|
|
|
|
(2)
|
Approve the Universal Display Corporation Annual Incentive Plan;
|
|
|
|
|
(3)
|
Approve an advisory resolution regarding executive officer compensation;
|
|
|
|
|
(4)
|
Ratify the appointment of KPMG LLP as our independent registered public accounting firm for 2013; and
|
|
|
|
|
(5)
|
Transact such other business as may properly come before the meeting or any postponements or adjournments thereof.
|
|
|
Sincerely,
|
|
|
/s/ Sidney D. Rosenblatt
|
|
|
Sidney D. Rosenblatt
|
|
|
Executive Vice President, Chief Financial Officer,
|
|
|
Treasurer and Secretary
|
|
(1)
|
the election of seven members of our Board of Directors to hold one-year terms;
|
|
|
|
|
(2)
|
a proposal to approve the Universal Display Corporation Annual Incentive Plan;
|
|
|
|
|
(3)
|
a proposal to approve an advisory resolution regarding executive officer compensation;
|
|
|
|
|
(4)
|
a proposal to ratify the appointment of KPMG LLP as our independent registered public accounting firm for 2013; and
|
|
|
|
|
(5)
|
such other business as may properly come before the meeting or any postponements or adjournments thereof.
|
|
|
NOMINEES FOR ELECTION AS DIRECTORS
|
|
||
|
|
|
|
|
Year First Became Director,
|
|
Name of Director
|
|
Age
|
|
Principal Occupations and Certain Directorships
|
|
|
|
|
|
|
|
Sherwin I. Seligsohn
|
|
77
|
|
Mr. Seligsohn is our Founder and has been the Chairman of our Board of Directors since June 1995. He also served as our Chief Executive Officer from June 1995 through December 2007, and as our President from June 1995 through May 1996. Mr. Seligsohn serves as the sole Director, President and Secretary of American Biomimetics Corporation, International Multi-Media Corporation, and Wireless Unified Network Systems Corporation. He was also previously the Chairman of the Board of Directors, President and Chief Executive Officer of Global Photonic Energy Corporation (“GPEC”) until April of 2012, when he resigned from his positions at GPEC. Since that time, Mr. Seligsohn's only relationship with GPEC is as a shareholder and option holder. From June 1990 to October 1991, Mr. Seligsohn was Chairman Emeritus of InterDigital Communications, Inc. (“InterDigital”), formerly International Mobile Machines Corporation. He founded InterDigital and from August 1972 to June 1990 served as its Chairman of the Board of Directors. Mr. Seligsohn is a member of the Industrial Advisory Board of the Princeton Institute for the Science and Technology of Materials (“PRISM”) at Princeton University.
|
|
|
|
|
|
|
|
Steven V. Abramson
|
|
61
|
|
Mr. Abramson is our President and Chief Executive Officer, and has been a member of our Board of Directors since May 1996. Mr. Abramson served as our President and Chief Operating Officer from May 1996 through December 2007. From March 1992 to May 1996, Mr. Abramson was Vice President, General Counsel, Secretary and Treasurer of Roy F. Weston, Inc., a worldwide environmental consulting and engineering firm. From December 1982 to December 1991, Mr. Abramson held various positions at InterDigital, including General Counsel, Executive Vice President and General Manager of the Technology Licensing Division. Mr. Abramson has also been a member of the Board of Directors of the OLED Association since its inception in 2008.
|
|
|
|
|
|
|
|
Sidney D. Rosenblatt
|
|
65
|
|
Mr. Rosenblatt is an Executive Vice President and has been our Chief Financial Officer, Treasurer and Secretary since June 1995. He also has been a member of our Board of Directors since May 1996. Mr. Rosenblatt was the owner of S. Zitner Company from August 1990 through August 2010 and served as its President from August 1990 through December 1998. From May 1982 to August 1990, Mr. Rosenblatt served as the Senior Vice President, Chief Financial Officer and Treasurer of InterDigital.
|
|
|
|
|
|
Year First Became Director,
|
|
Name of Director
|
|
Age
|
|
Principal Occupations and Certain Directorships
|
|
|
|
|
|
|
|
Leonard Becker
|
|
89
|
|
Mr. Becker has been a member of our Board of Directors since February 2001. For the last 40 years, Mr. Becker has been a general partner of Becker Associates, which is engaged in real estate investments and management. He served on the Board of Directors of American Business Financial Services, Inc. (OTCBB: “ABFIQ.PK”), as well as on its compensation and audit committees, until March 2007. He also previously served as a director of Eagle National Bank and Cabot Medical Corporation.
|
|
|
|
|
|
|
|
Elizabeth H. Gemmill
|
|
67
|
|
Ms. Gemmill has been a member of our Board of Directors since April 1997. Since March 1999, she has been Managing Trustee and, more recently, President of the Warwick Foundation until the Foundation was dissolved in 2012. From February 1988 to March 1999, Ms. Gemmill was Vice President and Secretary of Tasty Baking Company. Ms. Gemmill is the former Chairman of the Board of Philadelphia University (1998-2009) and serves on the Boards of Beneficial Mutual Bancorp, Inc., WHYY, Inc., and The Presbyterian Foundation. She previously served as a director of the Philadelphia College of Osteopathic Medicine, the YMCA of Philadelphia and Vicinity, and American Water Works Company, Inc. (NYSE: “AWK”) until it was sold in early 2003, and as a director of Philadelphia Consolidated Holdings Corporation (NASDAQ: “PHLY”) until it was sold in December 2008.
|
|
|
|
|
|
|
|
C. Keith Hartley
|
|
70
|
|
Mr. Hartley has been a member of our Board of Directors since September 2000. Since June 2000, he has been the President of Hartley Capital Advisors, a merchant banking firm. From August 1995 to May 2000, he was the managing partner of Forum Capital Markets LLC, an investment banking company. In the past, Mr. Hartley held the position of managing partner for Peers & Co. and Drexel Burnham Lambert, Inc. He also serves as a director of Idera Pharmaceuticals, Inc. (NASDAQ: “IDRA”) and Swisher International Group, Inc.
|
|
|
|
|
|
|
|
Lawrence Lacerte
|
|
60
|
|
Mr. Lacerte has been a member of our Board of Directors since October 1999. Since July 1998, he has been Chairman of the Board of Directors and Chief Executive Officer of Exponent Technologies, Inc., a company specializing in technology and Internet-related ventures. Prior to that time, he was the founder, Chairman of the Board of Directors and Chief Executive Officer of Lacerte Software Corp., which was sold to Intuit Corporation in June 1998.
|
|
•
|
reviewing our financial statements and discussing these statements and other relevant financial matters with management and our independent registered public accounting firm;
|
|
•
|
selecting and evaluating our independent registered public accounting firm and approving all audit engagement fees and terms;
|
|
•
|
pre-approving all audit and non-audit services provided to us, including the scope of such services, the procedures to be utilized and the compensation to be paid;
|
|
•
|
assessing the effectiveness of our internal control system and discussing this assessment with management and our independent registered public accounting firm;
|
|
•
|
reviewing our financial reporting and accounting standards and principles, significant changes in these standards and principles, or in their application, and key accounting decisions affecting our financial statements, including alternatives to, and the rationale for, these decisions;
|
|
•
|
discussing with management and our independent registered public accounting firm, as appropriate, our risk assessment and risk management policies, including our major exposures to financial risk and the steps taken by management to monitor and mitigate these exposures; and
|
|
•
|
reviewing and investigating any matters pertaining to the integrity of management, including any actual or potential conflicts of interest or allegations of fraud, and the adherence of management to our standards of business conduct.
|
|
|
Respectfully submitted by the Audit Committee
|
|
|
|
|
|
Elizabeth H. Gemmill (Chairperson)
|
|
|
Leonard Becker
|
|
|
C. Keith Hartley
|
|
|
Lawrence Lacerte
|
|
•
|
recommending to the full Board of Directors the base salary, incentive compensation and any other compensation for the Company's Chief Executive Officer, Chief Financial Officer and other executive officers;
|
|
•
|
recommending to the full Board of Directors the compensation for service as a member of the Board of Directors or any Board committees;
|
|
•
|
reviewing and approving or ratifying management's recommendations for equity compensation awards to other employees and consultants of the Company;
|
|
•
|
administering and discharging the duties imposed on the Compensation Committee under the terms of the Company's Equity Compensation Plan, Employee Stock Purchase Plan and Supplemental Executive Retirement Plan; and
|
|
•
|
performing such other functions and duties as are deemed appropriate by the full Board of Directors.
|
|
|
Respectfully submitted by the Compensation Committee
|
|
|
|
|
|
Elizabeth H. Gemmill (Chairperson)
|
|
|
Leonard Becker
|
|
|
C. Keith Hartley
|
|
|
Lawrence Lacerte
|
|
Diodes Incorporated
|
|
PLX Technology, Inc.
|
|
|
|
|
|
DTS, Inc.
|
|
Rogers Corporation
|
|
|
|
|
|
Exar Corporation
|
|
Standard Microsystems Corporation
|
|
|
|
|
|
InterDigital, Inc
|
|
Supertex, Inc.
|
|
|
|
|
|
Kopin Corporation
|
|
Tessera Technologies, Inc.
|
|
|
|
|
|
Littelfuse, Inc.
|
|
Volterra Semiconductor Corporation
|
|
MIPS Technologies, Inc.
|
|
Zoran Corporation
|
|
|
|
|
|
Monolithic Power Systems, Inc.
|
|
|
|
•
|
Base salaries;
|
|
•
|
Annual cash bonus awards;
|
|
•
|
Long-term incentive equity compensation awards;
|
|
•
|
Supplemental retirement benefits;
|
|
•
|
Special event awards; and
|
|
•
|
Perquisites and other benefits.
|
|
Name
|
|
Age
|
|
Years of Service
|
|
|
|
|
|
|
|
Steven V. Abramson
|
|
61
|
|
16
|
|
|
|
|
|
|
|
Sidney D. Rosenblatt
|
|
65
|
|
16
|
|
|
|
|
|
|
|
Julia J. Brown, Ph.D.
|
|
52
|
|
14
|
|
|
|
|
|
|
|
Janice K. Mahon
|
|
55
|
|
16
|
|
Name and Principal Position
|
|
Year
|
|
Salary ($)
|
|
Bonus
|
|
Stock
Awards ($)
|
|
Option
Awards ($)
|
|
Nonqualified Deferred Compensation
Earnings ($)
|
|
All Other
Compensation ($)
|
|
Total ($)
|
|
Steven V. Abramson
|
|
2012
|
|
561,400
|
|
438,750
|
|
438,708
(1)
|
|
—
|
|
559,881
(2)
|
|
31,110
(3)
|
|
2,029,849
|
|
President and Chief Executive
|
|
2011
|
|
542,487
|
|
—
|
|
649,969
(4)
|
|
—
|
|
607,315
(5)
|
|
29,311
(6)
|
|
1,829,082
|
|
Officer
|
|
2010
|
|
524,212
|
|
—
|
|
3,797,492
(7)
|
|
—
|
|
2,011,254
(8)
|
|
29,799
(9)
|
|
6,362,757
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sidney D. Rosenblatt
|
|
2012
|
|
561,400
|
|
438,750
|
|
438,708
(1)
|
|
—
|
|
407,161
(2)
|
|
35,250
(10)
|
|
1,881,269
|
|
Executive Vice President and
|
|
2011
|
|
542,487
|
|
—
|
|
649,969
(4)
|
|
—
|
|
—
(5)(11)
|
|
35,296
(12)
|
|
1,227,752
|
|
Chief Financial Officer
|
|
2010
|
|
524,212
|
|
—
|
|
3,797,492
(7)
|
|
—
|
|
3,319,980
(8)
|
|
35,283
(13)
|
|
7,676,967
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Julia J. Brown, Ph.D
|
|
2012
|
|
394,633
|
|
322,253
|
|
2,192,843
(1)
|
|
—
|
|
440,306
(2)
|
|
9,871
(14)
|
|
3,359,906
|
|
Senior Vice President and
|
|
2011
|
|
381,389
|
|
—
|
|
848,785
(4)(15)
|
|
74,900
(16)
|
|
411,312
(5)
|
|
9,676
(17)
|
|
1,726,062
|
|
Chief Technical Officer
|
|
2010
|
|
368,541
|
|
—
|
|
411,415
(7)(18)
|
|
—
|
|
917,461
(8)
|
|
9,778
(19)
|
|
1,707,195
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Janice K. Mahon
|
|
2012
|
|
276,405
|
|
130,018
|
|
1,163,412
(1)
|
|
—
|
|
271,092
(2)
|
|
9,757
(20)
|
|
1,850,684
|
|
Vice President of Technology
|
|
2011
|
|
267,058
|
|
—
|
|
458,331
(4)
|
|
52,430
(21)
|
|
338,498
(5)
|
|
9,582
(22)
|
|
1,125,899
|
|
Commercialization and General Manager, PHOLED Material Sales Business
|
|
2010
|
|
258,061
|
|
—
|
|
139,489
(7)
|
|
—
|
|
774,465
(8)
|
|
9,675
(23)
|
|
1,181,690
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mauro Premutico
|
|
2012
|
|
228,846
(24)
|
|
—
(25)
|
|
1,699,992
(1)(26)
|
|
—
|
|
—
|
|
6,312
(27)
|
|
1,935,150
|
|
Vice President Legal and
|
|
2011
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
General Manager, Patents and Licensing
|
|
2010
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(1)
|
|
This amount is based on the aggregate grant date fair value of all stock awards to the Named Executive Officer in 2012. The amount includes restricted shares of common stock granted to the Named Executive Officer on March 8, 2012. With respect to the unrestricted awards, shares of common stock were withheld for the payment of associated payroll taxes. These awards are discussed in greater detail in the section of this proxy statement entitled “Compensation Discussion and Analysis,” under the heading “Long-term incentive equity compensation awards,” and below under the section “Grants of Plan-Based Awards.”
|
|
|
|
|
|
(2)
|
|
Based on the difference between the actuarial present value of the accrued benefit under the SERP adopted by the Company on March 18, 2010 as of December 31, 2010, using a discount rate of 5.44%, and the actuarial present value of the accrued benefit under the SERP as of December 31, 2012, using a discount rate of 3.49%.
|
|
|
|
|
|
(3)
|
|
Based on (a) auto expense reimbursements and allowance of $9,391; (b) life and disability insurance premium payments of $14,219; and (c) 401(k) plan contributions of $7,500.
|
|
|
|
|
|
(4)
|
|
This amount is based on the aggregate grant date fair value of all stock awards to the Named Executive Officer in 2011. The amount includes both restricted and unrestricted shares of common stock granted to the Named Executive Officer on January 6, 2011. With respect to the unrestricted awards, shares of common stock were withheld for the payment of associated payroll taxes.
|
|
|
|
|
|
(5)
|
|
Based on the difference between the actuarial present value of the accrued benefit under the SERP adopted by the Company on March 18, 2010 as of December 31, 2010, using a discount rate of 5.44%, and the actuarial present value of the accrued benefit under the SERP as of December 31, 2011, using a discount rate of 4.44%.
|
|
|
|
|
|
(6)
|
|
Based on (a) auto expense reimbursements and allowance of $8,095; (b) life and disability insurance premium payments of $13,866; and (c) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(7)
|
|
This amount is based on the aggregate grant date fair value of all stock awards to the Named Executive Officer in 2010. The amount includes both restricted and unrestricted shares of common stock granted to the Named Executive Officer on January 6, 2010. In the case of Mr. Abramson and Mr. Rosenblatt, the amount also includes restricted shares of common stock granted to them on March 18, 2010. With respect to the unrestricted awards, shares of common stock were withheld for the payment of associated payroll taxes.
|
|
|
|
|
|
(8)
|
|
Based on the actuarial present value of the accrued benefit under the SERP as of December 31, 2010, using a discount rate of 5.44%.
|
|
|
|
|
|
(9)
|
|
Based on (a) auto expense reimbursements and allowance of $8,646; (b) life and disability insurance premium payments of $13,803; and (c) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(10)
|
|
Based on (a) auto expense reimbursements and allowance of $8,479; (b) life and disability insurance premium payments of $19,271; and (c) 401(k) plan contributions of $7,500.
|
|
|
|
|
|
(11)
|
|
The actual difference was a negative amount of $136,039, due to a change in Mr. Rosenblatt's benefit from joint and survivor to a single life annuity.
|
|
|
|
|
|
(12)
|
|
Based on (a) auto expense reimbursements and allowance of $8,284; (b) life and disability insurance premium payments of $19,662; and (c) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(13)
|
|
Based on (a) auto expense reimbursements and allowance of $8,469; (b) life and disability insurance premium payments of $19,464; and (c) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(14)
|
|
Based on (a) life and disability insurance premium payments of $2,371; and (b) 401(k) plan contributions of $7,500.
|
|
|
|
|
|
(15)
|
|
Also based on (a) the grant date fair value of 69 shares of common stock granted to Dr. Brown in 2011 as a bonus for the filing of patent applications and the issuance of patents that were assigned to the Company; and (b) 32 shares of common stock withheld for the payment of associated payroll taxes.
|
|
|
|
|
|
(16)
|
|
Based on 10,000 cash-settled SARs, valued using the Black-Scholes option pricing model, the fair value per SAR being $7.49 as of the grant date of January 6, 2011.
|
|
|
|
|
|
(17)
|
|
Based on (a) life and disability insurance premium payments of $2,326; and (b) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(18)
|
|
Also based on (a) the grant date fair value of 178 shares of common stock granted to Dr. Brown in 2010 as a bonus for the filing of patent applications and the issuance of patents that were assigned to the Company; and (b) 72 shares of common stock withheld for the payment of associated payroll taxes.
|
|
|
|
|
|
(19)
|
|
Based on (a) life and disability insurance premium payments of $2,428; and (b) 401(k) plan contributions of $7,350.
|
|
(20)
|
|
Based on (a) life and disability insurance premium payments of $2,257; and (b) 401(k) plan contributions of $7,500.
|
|
|
|
|
|
(21)
|
|
Based on $6,000 cash-settled SARs, valued using the Black-Scholes option pricing model, the fair value per SAR being $7.49 as of the grant date of January 6, 2011.
|
|
|
|
|
|
(22)
|
|
Based on (a) life and disability insurance premium payments of $2,232; and (b) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(23)
|
|
Based on (a) life and disability insurance premium payments of $2,325; and (b) 401(k) plan contributions of $7,350.
|
|
|
|
|
|
(24)
|
|
Mr. Premutico joined the Company in April, 2012, and this represents a pro-rated portion of his annual salary.
|
|
|
|
|
|
(25)
|
|
As was the case with the other Named Executive Officers, Mr. Premutico was awarded a bonus payment on March 8, 2013. The amount of the bonus awarded to Mr. Premutico was $127,500.
|
|
|
|
|
|
(26)
|
|
Based on the grant date fair value of 47,766 restricted shares of common stock. The closing price of the Company's common stock on the NASDAQ Global Market on April 16, 2012 (date of grant) was $35.59 per share. Mr. Premutico's special retention award vests ratably over a five-year period on each anniversary of the date of grant, subject to continued employment with the Company through the applicable vesting date.
|
|
|
|
|
|
(27)
|
|
Based on (a) life and disability insurance premium payments of $1,251; and (b) 401(k) plan contributions of $5,061.
|
|
•
|
Base salary, paid in cash;
|
|
•
|
Discretionary year-end bonus awards for 2011 performance, paid in cash;
|
|
•
|
Discretionary awards of unrestricted common stock granted as performance bonuses on January 6, 2011, January 6, 2010;
|
|
•
|
Discretionary awards of restricted common stock granted as long-term incentive equity compensation on March 8, 2012, January 6, 2011, January 6, 2010;
|
|
•
|
Special equity retention awards of restricted common stock granted as long-term incentive equity compensation to Mr. Abramson and Mr. Rosenblatt on March 18, 2010, to Dr. Brown and Ms. Mahon on January 6, 2011 and March 8, 2012, and to Mr. Premutico on April 16, 2012;
|
|
•
|
Cash-settled SARs granted to Dr. Brown and Ms. Mahon on January 6, 2011;
|
|
•
|
SERP benefits granted effective as of April 1, 2010 for Mr. Abramson, Mr. Rosenblatt, Dr. Brown and Ms. Mahon;
|
|
•
|
In the case of Dr. Brown, both cash and unrestricted stock awards granted as bonuses for the filing of patent applications and the issuance of patents on which she is a named inventor, and with respect to which the Company is the assignee; and
|
|
•
|
Perquisites in the form of auto expense allowances and reimbursements, life and disability insurance premium payments, and 401(k) plan matching contributions.
|
|
Name
|
|
Grant Date
|
|
All Other Stock Awards: Number of Shares of Stock (#)
|
|
All Other Option Awards: Number of Securities Underlying Options (#)
|
|
Exercise or Base Price of Option Awards ($/Share)
|
|
Grant Date Fair Value of Stock and Option Awards ($)
|
|
|
Steven V. Abramson..........
|
|
3/8/12
|
|
10,954
(1)
|
|
—
|
|
—
|
|
438,708
|
|
|
Sidney D. Rosenblatt........
|
|
3/8/12
|
|
10,954
(1)
|
|
—
|
|
—
|
|
438,708
|
|
|
Julia J. Brown, Ph.D.........
|
|
3/8/12
|
|
7,921
(1)
|
|
—
|
|
—
|
|
317,236
|
|
|
|
|
3/8/12
|
|
46,807
(2)
|
|
—
|
|
—
|
|
1,874,620
|
|
|
|
|
4/10/12
|
|
29
(3)
|
|
—
|
|
—
|
|
987
|
|
|
Janice K. Mahon...............
|
|
3/8/12
|
|
3,245
(1)
|
|
—
|
|
—
|
|
129,962
|
|
|
|
|
3/8/12
|
|
25,804
(2)
|
|
—
|
|
—
|
|
1,033,450
|
|
|
Mauro Premutico..............
|
|
4/16/12
|
|
47,766
(4)
|
|
—
|
|
—
|
|
1,699,992
|
|
|
(1
|
)
|
|
Consists of an award of restricted share units, which vest in equal increments over the first three anniversaries of the grant date, provided that the grantee is an employee of the Company at such time.
|
|
|
|
|
|
|
(2
|
)
|
|
Consists of a special retention award that vest ratably over a four-year period on each anniversary of the date of the award, subject to continued employment with the Company and a two-year holding period.
|
|
|
|
|
|
|
(3
|
)
|
|
Consists of an award of 29 immediately vesting shares of common stock, with a certificate for 18 of these shares having been issued and the remaining shares having been withheld for payment of associated payroll taxes.
|
|
|
|
|
|
|
(4
|
)
|
|
Consists of a special five-year restricted share award that vests ratably over five years is subject to continued employment with the Company and a two-year holding period.
|
|
•
|
Discretionary awards of restricted common stock granted as long-term incentive equity compensation, with the award vesting in equal increments over the first three anniversaries of the grant date;
|
|
•
|
Special equity retention awards of restricted common stock for Dr. Brown and Ms. Mahon that vest ratably over a four year period on each anniversary of the date of the award, subject to continued employment with the Company and a two-year holding period;
|
|
•
|
Special equity retention award of restricted common stock for Mr. Premutico, issued in connection with the commencement of his employment as our executive officer of the Company, that vest ratably over a five-year period on each anniversary of the date of the award, subject to continued employment with the Company and a two-year holding period; and
|
|
•
|
In the case of Dr. Brown, unrestricted stock awards granted as bonuses for the filing of patent applications and the issuance of patents on which she is a named inventor, and with respect to which the Company is the assignee.
|
|
|
|
Option Awards
|
|
Stock Awards
|
||||||
|
Name
|
|
Number of Securities Underlying Unexercised Options (#) Exercisable
|
|
Option Exercise Price ($)
|
|
Option Expiration Date
|
|
Number of Shares of Stock that Have Not Vested (#)
|
|
Market Value of Shares of Stock that Have Not Vested
(1)
($)
|
|
Steven V. Abramson................
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,400
|
|
16.94
|
|
1/20/2014
|
|
|
|
|
|
|
|
23,000
|
|
8.14
|
|
1/18/2015
|
|
|
|
|
|
|
|
27,000
(2)
|
|
10.51
|
|
12/30/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
173,760
|
|
4,451,731
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sidney D. Rosenblatt...............
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
16.94
|
|
1/20/2014
|
|
|
|
|
|
|
|
50,000
|
|
8.14
|
|
1/18/2015
|
|
|
|
|
|
|
|
50,000
|
|
10.51
|
|
12/30/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
173,760
|
|
4,451,731
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Julia J. Brown, Ph.D................
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500
|
|
9.43
|
|
6/7/2015
|
|
|
|
|
|
|
|
25,672
|
|
10.51
|
|
12/30/2015
|
|
|
|
|
|
|
|
250
|
|
11.89
|
|
1/17/2016
|
|
|
|
|
|
|
|
250
|
|
14.16
|
|
1/15/2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63,348
|
|
1,630,662
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Janice K. Mahon......................
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,817
|
|
13.92
|
|
12/23/2013
|
|
|
|
|
|
|
|
2,715
|
|
8.14
|
|
1/18/2015
|
|
|
|
|
|
|
|
20,000
|
|
10.51
|
|
12/30/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,447
|
|
831,292
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mauro Premutico.....................
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
—
|
|
—
|
|
47,766
|
|
1,223,765
|
|
(1
|
)
|
|
Based on the closing price of the Company's common stock on the NASDAQ Global Market on December 31, 2012.
|
|
|
|
|
|
|
(2
|
)
|
|
Mr. Abramson has a pecuniary interest in all but 4,000 of these stock options.
|
|
Name
|
|
Number of Shares Acquired on Exercise (#)
|
|
Value Realized on Exercise
(1)
($)
|
|
Number of Shares Acquired on Vesting (#)
|
|
Value Realized on Vesting
(2)
($)
|
|
Steven V. Abramson
|
|
18,400
|
|
414,368
|
|
69,815
(3)
|
|
2,756,985
(3)
|
|
Sidney D. Rosenblatt
|
|
40,000
|
|
1,243,202
|
|
69,815
|
|
2,756,985
|
|
Julia J. Brown, Ph.D
|
|
24,328
|
|
514,772
|
|
24,870
|
|
916,129
|
|
Janice K. Mahon
|
|
7,000
|
|
14,420
|
|
11,994
|
|
440,017
|
|
Mauro Premutico
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(1
|
)
|
|
Based on the difference between the closing price of our common stock on the NASDAQ Global Market on the date of exercise and the exercise price of the stock options or warrants exercised.
|
|
|
|
|
|
|
(2
|
)
|
|
Based on the closing price of our common stock on the NASDAQ Global Market on the date of vesting.
|
|
|
|
|
|
|
(3
|
)
|
|
Mr. Abramson has a pecuniary interest in all but 2,668 of these shares, the value of those shares on vesting being $98,289.
|
|
•
|
a lump-sum payment equal to two times the sum of the average annual base salary and the annual bonus to the individual, including any authorized deferrals, salary reduction amounts and any car allowance, and including the fair market dollar value equivalent of any bonus amounts paid in the form of stock options, SARs, warrants, stock awards or performance units;
|
|
•
|
a lump-sum payment equal to the estimated after-tax premium cost to the individual of continuing any Company-sponsored life, travel or accident insurance and disability insurance coverage for the individual (and where applicable, his or her spouse and dependents), based on coverage levels in effect immediately prior to the termination date (less any contributions that would have been required by the individual), for two years;
|
|
•
|
a lump-sum payment equal to the Company-provided contributions to which the individual would be entitled under the Company's 401(k) savings and retirement plans, assuming the individual continued working for the Company for two years at his or her annual base salary;
|
|
•
|
effective immediately preceding the Change in Control (but contingent upon the consummation of the Change in Control), full vesting of all outstanding, unvested equity awards held by the individual immediately preceding the Change in Control that have not yet become vested (and exercisable to the extent applicable), except that awards which vest based on the attainment of performance criteria would not automatically vest but would instead be governed by the terms of the plan or agreement evidencing the award;
|
|
•
|
continued group hospitalization, health and dental care coverage, at the level in effect as of the termination date (or generally comparable coverage) for the individual and, where applicable, the individual's spouse and dependents, for two years assuming the individual continued working for the Company;
|
|
•
|
a lump-sum payment equal to $10,000 for outplacement assistance services for two years; and
|
|
•
|
an additional payment to cover any excise tax imposed on the individual by reason of the individual receiving the payments and benefits specified above.
|
|
Name
|
Lump Sum Payment of Two Times Annual Base Salary
(1)
($)
|
Lump Sum Payment of Two Times Annual Bonus
(2)
($)
|
Lump Sum Payment for Accrued and Unused Paid Time Off and Sick Time ($)
|
Lump Sum Payment of Estimated After-Tax Cost to Continue Life, Travel and Disability Insurance for Two Years ($)
|
Lump Sum Payment of Estimated Contribu-tions Under 401(k) Savings and Retirement Plans for Two Years ($)
|
Estimated Value of Ongoing Payments to Continue Group Hospitaliza-tion, Health and Dental Coverage for Two Years ($)
|
Estimated Value of Unvested Stock Options and Stock Awards Subject to Accelerated Vesting
(3)
($)
|
Payment for Outplace-ment Assistance Services ($)
|
Value of Tax Reimburse-ment Payments on Account of Excise or Other Taxes ($)
|
Total Payments and Benefits ($)
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Steven V. Abramson
|
1,155,624
|
|
1,754,915
|
|
131,957
|
|
28,295
|
|
15,000
|
|
24,717
|
|
4,451,731
|
|
10,000
|
|
2,481,551
|
|
10,053,790
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Sidney D. Rosenblatt
|
1,155,624
|
|
1,754,915
|
|
75,336
|
|
39,569
|
|
15,000
|
|
23,838
|
|
4,451,731
|
|
10,000
|
|
2,326,847
|
|
9,852,860
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Julia J. Brown, Ph.D.
|
803,266
|
|
1,689,822
|
|
92,032
|
|
4,609
|
|
15,000
|
|
29,149
|
|
1,630,662
|
|
10,000
|
|
—
|
|
4,274,540
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Janice K. Mahon
|
553,531
|
|
916,697
|
|
62,190
|
|
4,348
|
|
15,000
|
|
29,149
|
|
831,292
|
|
10,000
|
|
778,005
|
|
3,200,212
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Mauro Premutico
|
680,000
|
|
—
(4)
|
|
12,894
|
|
4,729
|
|
15,000
|
|
41,549
|
|
1,223,765
|
|
10,000
|
|
883,527
|
|
2,871,464
|
|
|
(1
|
)
|
|
Under the Amended CIC Agreements, this is to be based on the highest monthly base salary paid or payable to the employee during the twenty-four (24) months prior to December 31, 2012, including any amounts earned but deferred. It is also to include any annual car allowance. For purposes of this calculation, the employee's bi-weekly salary as of the payment period ended on December 31, 2012 was utilized. Also, an annual car allowance of $6,000 is included for each of Mr. Abramson and Mr. Rosenblatt.
|
|
|
|
|
|
|
(2
|
)
|
|
Under the Amended CIC Agreements, this is to be based on the highest annual bonus to the employee for the last three full fiscal years prior to December 31, 2012, and is to include the fair market dollar value equivalent of any stock, restricted stock or stock options issued as bonus consideration, determined as of the date of issuance and without regard to any restrictions or vesting conditions.
|
|
|
|
|
|
|
(3
|
)
|
|
Assumes all unvested or restricted stock options and stock awards automatically vest on a Change of Control. Does not include restricted stock bonuses awarded in March 2013.
|
|
|
|
|
|
|
(4
|
)
|
|
As was the case with the other Named Executive Officers, Mr. Premutico was awarded a bonus payment on March 8, 2013. The amount of the bonus awarded to Mr. Premutico was $127,500. However, this did not factor into amounts that would have been payable to him on a termination at December 31, 2012.
|
|
•
|
any person first becomes the beneficial owner of securities of the Company (not including securities previously owned by such persons or any securities acquired directly from the Company) representing 30% or more of the then-outstanding voting securities of the Company;
|
|
•
|
the individuals who constitute our Board of Directors at the beginning of any 24-month period cease, for any reason other than death, to constitute at least a majority of our Board of Directors;
|
|
•
|
the Company consummates a merger or consolidation with any other corporation, except where the voting securities of the Company outstanding immediately prior to the merger or consolidation continue to represent at least 50% of the voting securities of the Company (or the surviving entity of the merger or consolidation or
|
|
•
|
the shareholders of the Company approve a plan of complete liquidation or dissolution of the Company, or an agreement is consummated for the sale or disposition by the Company of all or substantially all of its assets, excluding a sale or disposition by the Company of all or substantially all of its assets to an entity, at least 50% of the voting securities of which are owned by persons in substantially the same proportion as their ownership of the Company immediately prior to the sale; or
|
|
•
|
any person consummates a tender offer or exchange for voting stock of the Company and, directly or indirectly, becomes (in one or more transactions) the “beneficial owner” of securities of the Company representing a majority of the voting securities of the Company.
|
|
•
|
by the Company at the time of or within two years after a Change in Control, other than for the individual's death or incapacity for a period of 12 consecutive months, or for cause;
|
|
•
|
by the individual within two years after a Change in Control for (i) the Company's breach of the Amended CIC Agreement or any other material obligation of the Company to the individual, (ii) any significant reduction by the Company of the individual's authority, duties or responsibilities, (iii) any demotion or removal of the individual from his or her employment grade, compensation level or officer positions, or (iv) a relocation by more than 50 miles of the offices of the Company at which the individual principally works; and
|
|
•
|
by either the Company or the individual during the one year period immediately preceding a Change in Control, unless the Company establishes by clear and convincing evidence that the termination was for good faith business reasons not related to the Change in Control.
|
|
Name
|
|
Fees Earned or Paid in Cash ($)
|
|
Stock Awards ($)
|
|
Option Awards
(1)
($)
|
|
All Other Compensation ($)
|
|
Total ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leonard Becker……...
|
|
40,000
|
|
129,250
(2)
|
|
—
|
|
—
|
|
169,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Elizabeth H. Gemmill..
|
|
50,000
(3)
|
|
129,250
(2)
|
|
—
|
|
—
|
|
179,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C. Keith Hartley……...
|
|
40,000
|
|
129,250
(2)
|
|
—
|
|
—
|
|
169,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lawrence Lacerte……
|
|
40,000
|
|
129,250
(2)
|
|
—
|
|
—
|
|
169,250
|
|
(1
|
)
|
|
The aggregate numbers of shares issuable to each independent director upon the exercise of options outstanding as of December 31, 2012 were as follows: Mr. Becker - 0 shares; Ms. Gemmill - 75,000 shares; Mr. Hartley - 75,000 shares; and Mr. Lacerte - 0 shares. There were no restricted stock awards to any of our independent directors outstanding as of December 31, 2012.
|
|
|
|
|
|
|
(2
|
)
|
|
Aggregate grant date fair value of 5,000 shares approved for issuance as compensation for 2013, the closing price of the Company's common stock being $25.85 per share on the grant approval date of December 20, 2012 (for a total amount of $129,250).
|
|
|
|
|
|
|
(3
|
)
|
|
Includes additional cash compensation to Ms. Gemmill for her service as Chairperson of the Audit Committee and Compensation Committee of the Board of Directors.
|
|
Plan Category
|
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights (#)
|
|
Weighted-average exercise price of outstanding options, warrants and rights ($)
|
|
Number of securities remaining available for future issuance under equity compensation plans
(1)
(#)
|
|
Equity compensation plans approved by security holders………
|
|
828,230
|
|
11.58
|
|
2,343,651
(2)
|
|
|
|
|
|
|
|
|
|
Equity compensation plans not approved by security holders………
|
|
—
|
|
—
|
|
—
|
|
|
|
|
|
|
|
|
|
Total………………………………..
|
|
828,230
|
|
11.58
|
|
2,343,651
(2)
|
|
(1
|
)
|
|
Excludes securities reflected in the column entitled “Number of securities to be issued upon exercise of outstanding options, warrants and rights.”
|
|
|
|
|
|
|
(2
|
)
|
|
Includes 944,163 shares remaining available under the Company's Employee Stock Purchase Plan. No more than 12,500 shares are subject to purchase by each participant during any three-month purchase period under the Plan.
|
|
•
|
select participants in the AIP;
|
|
•
|
determine each participant's bonus award amount;
|
|
•
|
approve all bonus awards under the AIP;
|
|
•
|
establish and calculate achievement of performance goals; and
|
|
•
|
make all other determinations for the proper administration of the AIP.
|
|
Name
|
|
Base Salary ($)
|
|
Annual Incentive Target (% of Base)
|
|
Annual Incentive Target ($)
|
|
Steven V. Abramson
President and Chief Executive Officer
|
|
571,812
|
|
100
|
|
571,812
|
|
Sidney D. Rosenblatt
Executive Vice President and Chief Financial Officer
|
|
571,812
|
|
100
|
|
571,812
|
|
Julia J. Brown, Ph.D.
Chief Technical Officer, Senior Vice President
|
|
401,633
|
|
100
|
|
401,633
|
|
Janice K. Mahon
Vice President of Technology Commercialization and General Manager, PHOLED Material Sales Business
|
|
276,765
|
|
60
|
|
166,059
|
|
Mauro Premutico
Vice President Legal and General Manager, Patents and Licensing
|
|
340,000
|
|
60
|
|
204,000
|
|
Executive Officer Group (7 people)
|
|
2,784,318
|
|
50-100
|
|
2,330,248
|
|
Non-Executive Director Group
|
|
n/a
|
|
n/a
|
|
n/a
|
|
Non-Executive Officer Employee Group
|
|
n/a
|
|
n/a
|
|
n/a
|
|
Fee Category
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
Audit Fees
|
|
$358,500
(1)
|
|
$343,000
(2)
|
|
Audit-Related Fees
|
|
—
|
|
—
|
|
Tax Fees
|
|
$529,000
(3)
|
|
$60,000
(4)
|
|
All Other Fees
|
|
—
|
|
—
|
|
(1)
(2)
|
Consisted of fees relating to the audit of consolidated financial statements, the audit of internal control over financial reporting, quarterly reviews, and a statutory audit of the Company's subsidiary in Hong Kong.
Consisted of fees relating to the audit of consolidated financial statements, the audit of internal control over financial reporting, quarterly reviews, the issuance of a comfort letter and consent relating to a March 2011 common stock offering, and a statutory audit of the Company's subsidiary in Hong Kong.
|
|
|
|
|
(3)
(4)
|
Consisted primarily of fees relating to tax consultation for assisting with tax matters associated with business operations outside of the United States, as well as on certain domestic tax matters.
Consisted of fees relating to tax consultation for assisting with tax issues associated with business operations outside of the United States.
|
|
Title of Class
|
|
Name and Address
of Beneficial Owner
(1)
|
|
Number of Shares Beneficially Owned
(2)
(#)
|
|
Percentage Ownership
(2)
|
|
Common Stock
|
|
|
|
|
|
|
|
|
|
Scott Seligsohn
(3)(4)
……………………..
|
|
3,404,972
|
|
7.4%
|
|
|
|
Lori S. Rubenstein
(3)(5)
…………………
|
|
3,254,000
|
|
7.0%
|
|
|
|
Steven G. Winters
(3)(6)
………………….
|
|
3,176,000
|
|
6.9%
|
|
|
|
FMR LLC
(7)
…………………………….
|
|
6,045,960
|
|
13.1%
|
|
|
|
Discovery Capital Management, LLC
(8)
|
|
6,720,469
|
|
14.6%
|
|
|
|
|
|
|
|
|
|
Series A Preferred Stock
|
|
|
|
|
|
|
|
|
|
American Biomimetics Corporation
(6)(9)
|
|
200,000
|
|
100%
|
|
|
|
Sherwin I. Seligsohn
(9)
………………...
|
|
200,000
|
|
100%
|
|
(1)
|
Unless otherwise indicated, the address of each beneficial owner is 375 Phillips Boulevard, Ewing, New Jersey 08618.
|
|
|
|
|
(2)
|
Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of our common stock and Series A Preferred Stock beneficially owned by them. The percentage ownership for each beneficial owner listed above is based on 46,176,385 shares of our common stock and 200,000 shares of our Series A Preferred Stock outstanding as of the Record Date. In accordance with SEC rules, options or warrants to purchase shares of our common stock that were exercisable as of the Record Date, or would become exercisable within 60 days thereafter, are deemed to be outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing such person's percentage ownership, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person.
|
|
|
|
|
(3)
|
Includes (a) 1,500,000 shares of our common stock owned by the Sherwin I. Seligsohn Irrevocable Indenture of Trust dated July 29, 1993, FBO Lori S. Rubenstein (the “Rubenstein Trust”), of which Lori S. Rubenstein, Scott Seligsohn and Steven G. Winters are co-trustees; (b) 1,500,000 shares of our common stock owned by the Sherwin I. Seligsohn Irrevocable Indenture of Trust dated July 29, 1993, FBO Scott Seligsohn (the “Seligsohn Trust”), of which Lori S. Rubenstein, Scott Seligsohn and Steven G. Winters are co-trustees; and (c) 176,000 shares of our common stock owned by American Biomimetics Corporation, of which the Rubenstein Trust and Seligsohn Trust are the principal shareholders. Ms. Lori S. Rubenstein is Mr. Sherwin I. Seligsohn's adult daughter, and Mr. Scott Seligsohn is Mr. Sherwin I. Seligsohn's adult son.
|
|
|
|
|
(4)
|
Includes 7,750 options to purchase shares of our common stock and 221,222 shares of our common stock owned directly by Mr. Scott Seligsohn.
|
|
|
|
|
(5)
|
Includes 78,000 shares of our common stock owned directly by Ms. Rubenstein.
|
|
|
|
|
(6)
|
The address of these beneficial owners is c/o Cozen O'Connor, 1900 Market Street, Philadelphia, PA 19103.
|
|
|
|
|
(7)
|
Based solely on a Schedule 13G/A filed by FMR LLC and Edward C. Johnson 3d, Chairman of FMR LLC, on February 14, 2013. The reported address for each of FMR LLC and Edward C. Johnson 3d is 82 Devonshire Street, Boston, Massachusetts 02109.
|
|
|
|
|
(8)
|
Based solely on a Schedule 13G/A filed by Discovery Capital Management, LLC, Discovery Global Opportunity Master Fund, Ltd and Robert K. Citrone on February 14, 2013, and the most recent Statement of Changes in Beneficial Ownership on Form 4 filed by Discovery Global Opportunity Master Fund, Ltd., c/o Discovery Capital Management, LLC, on April 9, 2013. The reported address for each is 20 Marshall Street, South Norwalk, Connecticut 06854.
|
|
|
|
|
(9)
|
Mr. Sherwin I. Seligsohn, our Founder and Chairman of the Board, is the sole Director, Chairman, President and Secretary of American Biomimetics Corporation, which owns all 200,000 shares of our Series A Preferred Stock.
|
|
Title of Class
|
|
Name and Address
of Beneficial Owner
(1)
|
|
Number of Shares Beneficially Owned
(2)
(#)
|
|
Percentage Ownership
(2)
|
|
Common Stock
|
|
|
|
|
|
|
|
|
|
Sherwin I. Seligsohn.…………………
|
|
451,220
(3)
|
|
1.3%
|
|
|
|
Steven V. Abramson…………………..
|
|
354,816
|
|
*
|
|
|
|
Sidney D. Rosenblatt………………....
|
|
332,482
(4)(5)
|
|
1.0%
|
|
|
|
Julia J. Brown, Ph.D………………….
|
|
201,532
|
|
*
|
|
|
|
Janice K. Mahon……………………...
|
|
61,695
|
|
*
|
|
|
|
Mauro Premutico……………………...
|
|
47,766
|
|
*
|
|
|
|
Leonard Becker…………………….....
|
|
36,250
|
|
*
|
|
|
|
Elizabeth H. Gemmill………………...
|
|
90,620
|
|
*
|
|
|
|
C. Keith Hartley……………………....
|
|
84,077
(6)
|
|
*
|
|
|
|
Lawrence Lacerte……………………..
|
|
793,560
(7)(8)
|
|
1.7%
|
|
|
|
All directors and named executive officers as a group (10 persons)……....
|
|
2,454,018
|
|
6.4%
|
|
|
|
|
|
|
|
|
|
Series A Preferred Stock
|
|
|
|
|
|
|
|
|
|
Sherwin I. Seligsohn.…………………
|
|
200,000
(9)
|
|
100%
|
|
*
|
Represents less than 1% of our outstanding common stock.
|
|
|
|
|
(1)
|
Unless otherwise indicated, the address of each beneficial owner is 375 Phillips Boulevard, Ewing, New Jersey 08618.
|
|
|
|
|
(2)
|
Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned by them. The percentage ownership for each beneficial owner listed above is based on 46,176,385 shares of our common stock and 200,000 shares of our Series A Preferred Stock outstanding as of the Record Date. In accordance with SEC rules, options or warrants to purchase shares of our common stock that were exercisable as of the Record Date, or would become exercisable within 60 days thereafter, are deemed to be outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing such person's percentage ownership, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The numbers of shares of common stock listed include the following number of shares issuable upon the exercise of outstanding warrants or options: Sherwin I. Seligsohn - 140,500; Steven V. Abramson - 64,400; Sidney D. Rosenblatt - 140,000; Julia J. Brown - 26,627; Janice K. Mahon - 25,532; Mauro Premutico - 0; Leonard Becker - 0; Elizabeth H. Gemmill - 75,000; C. Keith Hartley - 75,000; and Lawrence Lacerte - 0.
|
|
|
|
|
(3)
|
Includes 176,000 shares of our common stock owned by American Biomimetics Corporation, of which Mr. Sherwin I. Seligsohn is the sole Director, Chairman, President and Secretary. Also includes 21,000 shares of our common stock owned by The Seligsohn Foundation, of which Mr. Sherwin I. Seligsohn is the sole trustee. Does not include (i) 1,500,000 shares of our common stock owned by the Rubenstein Trust; (ii) 1,500,000 shares of our common stock owned by the Seligsohn Trust; (iii) 78,000 shares of our common stock owned by Ms. Lori S. Rubenstein; and (iv) 7,750 options to purchase shares of our common stock and 221,222 shares of our common stock owned by Mr. Scott Seligsohn, as to which in each case Mr. Sherwin I. Seligsohn disclaims beneficial ownership.
|
|
|
|
|
(4)
(5)
|
Includes 3,250 shares of our common stock held by Mr. Rosenblatt's children and being reported as beneficially owned by him.
Includes 110,836 shares of our common stock held by the Rosenblatt Family Limited Partnership, a limited partnership of which Mr. Rosenblatt is the sole general partner and he and his children are the sole limited partners and are being reported as beneficially owned by him.
|
|
|
|
|
(6)
|
Includes 23,528 shares of our common stock owned by Mr. Hartley's Defined Benefit Pension Plan.
|
|
(7)
(8)
|
Includes 8,000 shares of our common stock held by Mr. Lacerte's children and being reported as beneficially owned by him.
These shares of common stock held by Mr. Lacerte are pledged as security for a margin loan.
|
|
|
|
|
(9)
|
Mr. Sherwin I. Seligsohn is the sole Director, Chairman, President and Secretary of American Biomimetics Corporation, which owns all 200,000 shares of our Series A Preferred Stock.
|
|
•
|
reviewing and considering reports from and information provided by management to the Board and its committees on topics relating to the risks that we face, including, without limitation, the status of current and anticipated developments of our technology, access to debt and equity capital markets, existing and potential legal claims against us and various other matters relating to our business;
|
|
•
|
the direct oversight of specific areas of our business by our Compensation Committee and Audit Committee; and
|
|
•
|
reviewing and considering reports from, and information provided by, our auditors and other outside consultants regarding various areas of potential risk, including, among others, those relating to our compensation practices and our internal control over financial reporting.
|
|
|
Sincerely,
|
|
|
/s/ Sidney D. Rosenblatt
|
|
|
Sidney D. Rosenblatt
|
|
|
Executive Vice President, Chief Financial Officer,
|
|
|
Treasurer and Secretary
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|